New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential
- 28 January 2009
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 12 (1-2) , 17-27
- https://doi.org/10.1016/j.drup.2008.12.002
Abstract
No abstract availableKeywords
This publication has 173 references indexed in Scilit:
- A Novel Class of Small Molecule Inhibitors of Hsp90ACS Chemical Biology, 2008
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasionOncogene, 2008
- Targeting the oncogene and kinome chaperone CDC37Nature Reviews Cancer, 2008
- A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasionOncogene, 2007
- Structures of GRP94-Nucleotide Complexes Reveal Mechanistic Differences between the hsp90 ChaperonesMolecular Cell, 2007
- ER chaperones in mammalian development and human diseasesFEBS Letters, 2007
- Extracellular heat shock protein-90α: linking hypoxia to skin cell motility and wound healingThe EMBO Journal, 2007
- An Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone FunctionPublished by Elsevier ,2007
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Proceedings of the National Academy of Sciences, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006